|
|
Volumn 6, Issue 5, 2004, Pages 336-342
|
|
Targeting cytokines beyond tumor necrosis factor-alpha and interleukin-1 in rheumatoid arthritis.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
CYTOKINE;
IMMUNOGLOBULIN G;
INFLIXIMAB;
INTERLEUKIN 1;
MONOCLONAL ANTIBODY;
TNFR FC FUSION PROTEIN;
TNFR-FC FUSION PROTEIN;
TUMOR NECROSIS FACTOR ALPHA;
TUMOR NECROSIS FACTOR RECEPTOR;
ANIMAL;
BLOOD;
CLINICAL TRIAL;
COMPARATIVE STUDY;
CONTROLLED CLINICAL TRIAL;
DISEASE COURSE;
DISEASE MODEL;
DRUG ANTAGONISM;
FEMALE;
HAPLORHINI;
HUMAN;
MALE;
METABOLISM;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PROGNOSIS;
RANDOMIZED CONTROLLED TRIAL;
REVIEW;
RHEUMATOID ARTHRITIS;
RISK ASSESSMENT;
TREATMENT OUTCOME;
ANIMALS;
ANTIBODIES, MONOCLONAL;
ARTHRITIS, RHEUMATOID;
CLINICAL TRIALS, PHASE I;
CLINICAL TRIALS, PHASE II;
CYTOKINES;
DISEASE MODELS, ANIMAL;
DISEASE PROGRESSION;
FEMALE;
HAPLORHINI;
HUMANS;
IMMUNOGLOBULIN G;
INTERLEUKIN-1;
MALE;
PROGNOSIS;
RANDOMIZED CONTROLLED TRIALS;
RECEPTORS, TUMOR NECROSIS FACTOR;
RISK ASSESSMENT;
TREATMENT OUTCOME;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 13444251815
PISSN: 15233774
EISSN: None
Source Type: Journal
DOI: 10.1007/s11926-004-0007-2 Document Type: Review |
|
Times cited : (18)
|
|
References (61)
|
